ArticleJournal of medical systems2025
Predicting the Regulatory Dynamics of AML Disease Progression from Longitudinal Multi-Modal Clinical Data.
Article in Journal of medical systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Acute Myeloid Leukemia (AML) is a complex and heterogeneous disease identified by severe clinical progression, fast cellular proliferation, and often high mortality rates. Incorporating diverse longitudinal information on patients' medical histories is essential for developing effective disease predictive models applicable to both research and clinical settings. Here, we present a robust methodology for discovering the regulation of disease progression dynamics from a novel longitudinal, multimodal clinical dataset of patients diagnosed with AML. The medical data were analyzed to reveal the main clinical, genetic, and treatment features modulating disease progression. To discover dynamic mathematical models at the systems level-including the necessary regulatory interactions, parameters, and disease drivers-predictive of AML progression, we developed a de novo inference algorithm based on high-performance evolutionary computation. The results demonstrate that the predictive methodology could accurately estimate the drivers and clinical dynamics of AML progression in terms of blast percentages for both training and novel patients. This approach effectively predicted AML drivers, their mechanistic interactions, and disease progression by leveraging the heterogeneous and longitudinal dynamics of patients' clinical data. Importantly, this methodology shows significant potential for modeling progression dynamics in other acute diseases, providing a flexible and adaptable framework for advancing clinical and translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.